Molecular Mimics of the Tumour Antigen MUC1

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  James, Tharappel C ^a   Bond, Ursula ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; MUCIN 1; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN FUNCTION; ANTIGEN STRUCTURE; ARTICLE; BIOPANNING; CELL MATURATION; CYTOKINE RELEASE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; IMMUNOSTIMULATION; IN VITRO STUDY; ISOELECTRIC POINT; MOLECULAR MIMICRY; MOUSE; NONHUMAN; PEPTIDE LIBRARY; PHAGE DISPLAY; SEQUENCE HOMOLOGY; T LYMPHOCYTE ACTIVATION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANTIGENS, CD14; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CROSS REACTIONS; DENDRITIC CELLS; HUMANS; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; MUCIN-1; PEPTIDES; T-LYMPHOCYTES;

EID: 84869105800     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049728     Document Type: Article

References (44)

1. Caux C, Zitvogel L, (2012) Recent successes of cancer immunotherapy: a new dimension in personalized medicine? Target Oncol 7: 1-2.
2. Whiteside TL, (2012) Disarming suppressor cells to improve immunotherapy. Cancer Immunol Immunother 61: 283-288.
3. Wicherek L, Jozwicki W, Windorbska W, Roszkowski K, Lukaszewska E, et al. (2011) Analysis of Treg cell population alterations in the peripheral blood of patients treated surgically for ovarian cancer- a preliminary report. Am J Reprod Immunol 66: 444-450.
4. Bray SM, Vujanovic L, Butterfield LH, (2011) Dendritic cell-based vaccines positively impact natural killer and regulatory T cells in hepatocellular carcinoma patients. Clin Dev Immunol 2011: 249281.
5. Shirakura Y, Mizuno Y, Wang L, Imai N, Amaike C, et al. (2012) T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/gammacnull mice. Cancer Sci 103: 17-25.
6. Renkvist N, Castelli C, Robbins PF, Parmiani G, (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50: 3-15.
7. Mellman I, Coukos G, Dranoff G, (2011) Cancer immunotherapy comes of age. Nature 480: 480-489.
8. Hurwitz AA, Watkins SK, (2012) Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells. Cancer Immunol Immunother 61: 289-293.
9. Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P, (2011) Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy 31: 813-828.
10. Nisonoff A, Lamoyi E, (1981) Implications of the presence of an internal image of the antigen in anti-idiotypic antibodies: possible application to vaccine production. Clin Immunol Immunopathol 21: 397-406.
11. Raychaudhuri S, Saeki Y, Fuji H, Kohler H, (1986) Tumor-specific idiotype vaccines. I. Generation and characterization of internal image tumor antigen. J Immunol 137: 1743-1749.
12. Raychaudhuri S, Saeki Y, Syma, Kohler H (1986) Method and means for selection of anti-idiotype antibodies and their use for the diagnosis, monitoring, treatment and/or prevention of cancer, autoimmune or infectious disease. WIPO Patent Application WO/1989/005309.
13. Kennedy RC, Dreesman GR, Kohler H, (1985) Vaccines Utilizing Internal Image Anti-idiotypic Antibodies that Mimic Antigens of Infectious Organisms. Biotechniques 3: 404-410.
14. Kennedy RC, Eichberg JW, Dreesman GR, (1986) Lack of genetic restriction by a potential anti-idiotype vaccine for type B viral hepatitis. Virology 148: 369-374.
15. Herlyn D, Ross AH, Koprowski H, (1986) Anti-idiotypic antibodies bear the internal image of a human tumor antigen. Science 232: 100-102.
16. Elaine D, Dorothee H, Hilary K, Kevin R, Tadeusz W (1985) Immune response to tumours and viruses induced by anti-idiotype antibodies European Patent Organisation EP0141783 (A2) - 1985-05-15.
17. Arnaiz B, Madrigal-Estebas L, Todryk S, James TC, Doherty DG, et al. (2006) A novel method to identify and characterise peptide mimotopes of heat shock protein 70-associated antigens. J Immune Based Ther Vaccines 4: 2.
18. Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV, et al. (2010) MUC1 oncogene amplification correlates with protein overexpression in invasive breast carcinoma cells. Cancer Genet Cytogenet 201: 102-110.
19. Singh AP, Chaturvedi P, Batra SK, (2007) Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res 67: 433-436.
20. Baldus SE, Monig SP, Huxel S, Landsberg S, Hanisch FG, et al. (2004) MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res 10: 2790-2796.
21. Sachdeva M, Mo YY, (2010) MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 70: 378-387.
22. Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ, (2000) The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol 165: 3730-3741.
23. Tang CK, Katsara M, Apostolopoulos V, (2008) Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines 7: 963-975.
24. Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ, (2001) Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 85: 273-278.
25. Siebke C, James TC, Cummins R, O'Grady T, Kay E, et al. (2012) Phage display biopanning identifies the translation initiation and elongation factors (IF1alpha-3 and eIF-3) as components of Hsp70-peptide complexes in breast tumour cells. Cell Stress Chaperones 17: 145-156.
26. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988.
27. Fleischer K, Schmidt B, Kastenmuller W, Busch DH, Drexler I, et al. (2004) Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro. J Immunol 172: 162-169.
28. Thie H, Toleikis L, Li J, von Wasielewski R, Bastert G, et al. (2011) Rise and fall of an anti-MUC1 specific antibody. PLoS One 6: e15921.
29. Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, et al. (2012) Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci U S A 109: 261-266.
30. Blixt O, Bueti D, Burford B, Allen D, Julien S, et al. (2011) Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res 13: R25.
31. Graves CR, Robertson JF, Murray A, Price MR, Chapman CJ, (2005) Malignancy-induced autoimmunity to MUC1: initial antibody characterization. J Pept Res 66: 357-363.
32. Quinlin IS, Burnside JS, Dombrowski KE, Phillips CA, Dolby N, et al. (2007) Context of MUC1 epitope: immunogenicity. Oncol Rep 17: 453-456.
33. Heukamp LC, van der Burg SH, Drijfhout JW, Melief CJ, Taylor-Papadimitriou J, et al. (2001) Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice. Int J Cancer 91: 385-392.
34. Tsang KY, Palena C, Gulley J, Arlen P, Schlom J, (2004) A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1. Clin Cancer Res 10: 2139-2149.
35. Luo D, Qi W, Ma J, Wang YJ, Wishart D, (2000) Molecular mimicry of human tumor antigen by heavy chain CDR3 sequence of the anti-idiotypic antibody. J Biochem 128: 345-347.
36. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, et al. (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15: 5323-5337.
37. Rong Y, Qin X, Jin D, Lou W, Wu L, et al. (2011) A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Clin Exp Med.
38. Sorensen AL, Reis CA, Tarp MA, Mandel U, Ramachandran K, et al. (2006) Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 16: 96-107.
39. Ryan SO, Turner MS, Gariepy J, Finn OJ, (2010) Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Res 70: 5788-5796.
40. Kaiser A, Gaidzik N, Westerlind U, Kowalczyk D, Hobel A, et al. (2009) A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response. Angew Chem Int Ed Engl 48: 7551-7555.
41. Yuan W, Xia G, Zhao C, Sui C, Ma J, (2012) Anti-idiotypic single chain mimicking CA125 linked with tuftsin provides protective immunity against ovarian cancer in mice. Mol Med Report 5: 388-394.
42. Wilkinson RW, Ross EL, Lee-MacAry AE, Laylor R, Burchell J, et al. (2000) A transgenic mouse model for tumour immunotherapy: induction of an anti-idiotype response to human MUC1. Br J Cancer 83: 1202-1208.
43. Mitchell MS, (2002) Cancer vaccines, a critical review-Part II. Curr Opin Investig Drugs 3: 150-158.
44. Westerlind U, Kunz H, (2011) Synthetic vaccines from tumor-associated glycopeptide antigens. Chimia (Aarau) 65: 30-34.